# Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

> **NCT01708954** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 125 (actual)

## Conditions studied

- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **DRUG:** Cabozantinib S-malate
- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01708954
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-02-13
- **Primary completion:** 2015-08-14
- **Final completion:** 2027-03-31
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01708954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01708954, "Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01708954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*